Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality
Copyright © 2022 Lavis, Morra, Orte Cano, Albayrak, Corbière, Olislagers, Dauby, Del Marmol, Marchant, Decaestecker, Mascart, De Vos, Van de Borne, Salmon, Remmelink, Parmentier, Cardozo and Bondue..
Background: Chemerin is an extracellular protein with chemotactic activities and its expression is increased in various diseases such as metabolic syndrome and inflammatory conditions. Its role in lung pathology has not yet been extensively studied but both known pro- and anti-inflammatory properties have been observed. The aim of our study was to evaluate the involvement of the chemerin/ChemR23 system in the physiopathology of COVID-19 with a particular focus on its prognostic value.
Methods: Blood samples from confirmed COVID-19 patients were collected at day 1, 5 and 14 from admission to Erasme Hospital (Brussels - Belgium). Chemerin concentrations and inflammatory biomarkers were analyzed in the plasma. Blood cells subtypes and their expression of ChemR23 were determined by flow cytometry. The expression of chemerin and ChemR23 was evaluated on lung tissue from autopsied COVID-19 patients by immunohistochemistry (IHC).
Results: 21 healthy controls (HC) and 88 COVID-19 patients, including 40 in intensive care unit (ICU) were included. Plasma chemerin concentration were significantly higher in ICU patients than in HC at all time-points analyzed (p<0.0001). Moreover, they were higher in deceased patients compared to survivors (p<0.05). Logistic univariate regression and multivariate analysis demonstrated that chemerin level at day 14 of admission was an independent risk factor for death. Accordingly, chemerin levels correlated with inflammatory biomarkers such as C-reactive protein and tumor necrosis factor α. Finally, IHC analysis revealed a strong expression of ChemR23 on smooth muscle cells and chemerin on myofibroblasts in advanced acute respiratory distress syndrome (ARDS).
Discussion: Increased plasma chemerin levels are a marker of severity and may predict death of COVID-19 patients. However, multicentric studies are needed, before chemerin can be considered as a biomarker of severity and death used in daily clinical practice. Further studies are also necessary to identify the precise mechanisms of the chemerin/ChemR23 system in ARDS secondary to viral pneumonia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 13(2022) vom: 01., Seite 941663 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lavis, Philomène [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ARDS |
|---|
| Anmerkungen: |
Date Completed 30.08.2022 Date Revised 30.08.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2022.941663 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345496051 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345496051 | ||
| 003 | DE-627 | ||
| 005 | 20231226205206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.941663 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345496051 | ||
| 035 | |a (NLM)36032171 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lavis, Philomène |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2022 | ||
| 500 | |a Date Revised 30.08.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Lavis, Morra, Orte Cano, Albayrak, Corbière, Olislagers, Dauby, Del Marmol, Marchant, Decaestecker, Mascart, De Vos, Van de Borne, Salmon, Remmelink, Parmentier, Cardozo and Bondue. | ||
| 520 | |a Background: Chemerin is an extracellular protein with chemotactic activities and its expression is increased in various diseases such as metabolic syndrome and inflammatory conditions. Its role in lung pathology has not yet been extensively studied but both known pro- and anti-inflammatory properties have been observed. The aim of our study was to evaluate the involvement of the chemerin/ChemR23 system in the physiopathology of COVID-19 with a particular focus on its prognostic value | ||
| 520 | |a Methods: Blood samples from confirmed COVID-19 patients were collected at day 1, 5 and 14 from admission to Erasme Hospital (Brussels - Belgium). Chemerin concentrations and inflammatory biomarkers were analyzed in the plasma. Blood cells subtypes and their expression of ChemR23 were determined by flow cytometry. The expression of chemerin and ChemR23 was evaluated on lung tissue from autopsied COVID-19 patients by immunohistochemistry (IHC) | ||
| 520 | |a Results: 21 healthy controls (HC) and 88 COVID-19 patients, including 40 in intensive care unit (ICU) were included. Plasma chemerin concentration were significantly higher in ICU patients than in HC at all time-points analyzed (p<0.0001). Moreover, they were higher in deceased patients compared to survivors (p<0.05). Logistic univariate regression and multivariate analysis demonstrated that chemerin level at day 14 of admission was an independent risk factor for death. Accordingly, chemerin levels correlated with inflammatory biomarkers such as C-reactive protein and tumor necrosis factor α. Finally, IHC analysis revealed a strong expression of ChemR23 on smooth muscle cells and chemerin on myofibroblasts in advanced acute respiratory distress syndrome (ARDS) | ||
| 520 | |a Discussion: Increased plasma chemerin levels are a marker of severity and may predict death of COVID-19 patients. However, multicentric studies are needed, before chemerin can be considered as a biomarker of severity and death used in daily clinical practice. Further studies are also necessary to identify the precise mechanisms of the chemerin/ChemR23 system in ARDS secondary to viral pneumonia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ARDS | |
| 650 | 4 | |a CMKLR1 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ChemR23 | |
| 650 | 4 | |a chemerin | |
| 650 | 4 | |a prediction | |
| 650 | 4 | |a survival | |
| 650 | 4 | |a viral pneumonia | |
| 650 | 7 | |a Chemokines |2 NLM | |
| 650 | 7 | |a Intercellular Signaling Peptides and Proteins |2 NLM | |
| 650 | 7 | |a Receptors, Chemokine |2 NLM | |
| 700 | 1 | |a Morra, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Orte Cano, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Albayrak, Nurhan |e verfasserin |4 aut | |
| 700 | 1 | |a Corbière, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Olislagers, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Dauby, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Del Marmol, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Marchant, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Decaestecker, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Mascart, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a De Vos, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Van de Borne, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Salmon, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Remmelink, Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Parmentier, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Cardozo, Alessandra Kupper |e verfasserin |4 aut | |
| 700 | 1 | |a Bondue, Benjamin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 13(2022) vom: 01., Seite 941663 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:01 |g pages:941663 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2022.941663 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 01 |h 941663 | ||